- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266161
Multiple Dose Dental Pain Study Of Ibuprofen Extended Release
August 13, 2018 updated by: Pfizer
A Multiple Dose Dental Pain Study Of An Ibuprofen 600 Mg Extended Release Caplet
The study hypothesis is that single and multiple doses of ibuprofen 600 mg ER caplets provide analgesic efficacy superior to placebo over 12-hour dosing intervals.
Study Overview
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78705
- Premier Research
-
Austin, Texas, United States, 78705
- Central Texas Oral Surgery Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 40 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 16 to 40 years of age
- Subjects who undergo surgical removal of at least two third molars
- One of which must be a partial or full bony mandibular impaction
- Subjects must have at least moderate baseline pain (a score of 2 on the categorical pain severity rating scale) confirmed by a score of at least 50 mm on the 100-mm visual analog scale-pain severity rating scale (VAS-PSR)
Exclusion Criteria:
- Acute localized dental infection at the time of surgery that could confound the post-surgical evaluation
- Presence or history of any significant organ disease
- Use of prescription or OTC first generation antihistamines
- Females who are pregnant, lactating or of childbearing potential and not using a medically approved method to prevent pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
One placebo caplet dosed at times 0, 12, 24 and 36 hours
|
|
Experimental: Ibuprofen 600 mg extended release
|
One 600 mg caplet dosed at 0, 12, 24 and 36 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)
Time Frame: Baseline to 12 hours
|
SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores.
5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0 equals [=] none, 1=a little, 2=some, 3=a lot, 4=complete).
4-point categorical scale for PI: "How much pain do you have at this time?"
(0=none, 1=mild, 2=moderate, 3=severe).
PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity.
SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.
|
Baseline to 12 hours
|
|
Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose
Time Frame: 8 to 12 hours
|
SPRID is time-weighted sum of PR plus PID (PRID) scores.
5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete).
4-point categorical scale for pain intensity: "How much pain do you have at this time?"
(0=none, 1=mild, 2=moderate, 3=severe).
PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity.
SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.
|
8 to 12 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time-weighted Sum of Pain Intensity Difference (SPID) Scores
Time Frame: 0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours
|
SPID is a derived endpoint from PID scores.
For pain intensity, "How much pain do you have at this time?"
answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe).
PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity.
SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.
|
0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours
|
|
Time to First Dose of Rescue Medication After First Dose of Study Drug
Time Frame: Baseline to 12 hours
|
During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed).
The time at which rescue medication was taken was recorded.
|
Baseline to 12 hours
|
|
Percentage of Participants Taking Rescue Medication
Time Frame: Baseline to 48 hours
|
Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.
|
Baseline to 48 hours
|
|
Pain Relief (PR) Scores
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
|
A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: "How much relief do you have from your starting pain?" Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete.
Higher score indicated more pain relief.
|
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
|
|
Pain Intensity Difference (PID) Scores
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours
|
For pain intensity, "How much pain do you have at this time?"
answered on a 4-point categorical scale.
Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe.
PID score=baseline pain intensity score minus score at each time point.
PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).
|
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours
|
|
Pain Relief Combined With Pain Intensity (PRID) Scores
Time Frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
|
PRID score=PR plus PID.
5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete).
4-point categorical scale for pain intensity: "How much pain do you have at this time?"
(0=none, 1=mild, 2=moderate, 3=severe).
PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement.
PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.
|
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
|
|
Time-weighted Sum of Pain Relief Scores (TOTPAR)
Time Frame: 0-12 hours, 8-12 hours
|
TOTPAR is a derived endpoint from PR scores.
5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete).
TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best).
TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).
|
0-12 hours, 8-12 hours
|
|
Number of Doses of Rescue Medication Used
Time Frame: 0-12, 12-24, 24-36, 36-48, 0-48 hours
|
0-12, 12-24, 24-36, 36-48, 0-48 hours
|
|
|
Time to Confirmed First Perceptible Relief
Time Frame: Baseline to 12 hours
|
The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch.
Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug.
Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.
|
Baseline to 12 hours
|
|
Time to Meaningful Relief
Time Frame: Baseline to 12 hours
|
Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.
|
Baseline to 12 hours
|
|
Participant Global Evaluation Score
Time Frame: 24 and 48 hours
|
Participants responded, on a 6-point categorical scale, to the following question: "How would you rate this medication as a pain-reliever?" Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.
|
24 and 48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2010
Primary Completion (Actual)
March 31, 2011
Study Completion (Actual)
March 31, 2011
Study Registration Dates
First Submitted
December 22, 2010
First Submitted That Met QC Criteria
December 22, 2010
First Posted (Estimate)
December 24, 2010
Study Record Updates
Last Update Posted (Actual)
August 15, 2018
Last Update Submitted That Met QC Criteria
August 13, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Stomatognathic Diseases
- Tooth Diseases
- Facial Pain
- Toothache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- B3491001
- AK-10-13 (Other Identifier: Alias Study Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
noiVita SrlsUniversity of Eastern PiedmontCompletedCervical Pain | Pain Management | Lumbar Pain | Muscular | Chronic Pain (Back / Neck)Italy
-
Chinese University of Hong KongNot yet recruitingPain, Acute | Chronic Post Operative Pain | Pain, ChronicHong Kong
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of SaskatchewanRoyal University Hospital FoundationCompletedPain | Pain, Acute | Pain, Chronic | Pain, IntractableCanada
Clinical Trials on Ibuprofen 600 mg ER
-
SCOLR Pharma, Inc.AAIPharma; Jean Brown ResearchCompletedPain | Post-Operative Pain | Third Molar ExtractionUnited States
-
Overseas Pharmaceuticals, Ltd.Virginia Contract Research Organization Co., Ltd.Terminated
-
Ohio State UniversityCompleted
-
University of New MexicoCompletedAcute Kidney InjuryUnited States
-
King Abdulaziz UniversityCompleted
-
Reckitt Benckiser Inc.Completed
-
Boehringer IngelheimCompletedHidradenitis SuppurativaSpain, Norway, Australia, United States, Belgium, Germany, Italy, Canada, Czechia, France, Poland, Netherlands
-
Aziende Chimiche Riunite Angelini Francesco S.p.ATFS Trial Form SupportRecruitingUncomplicated Non Specific Acute Low Back PainPoland, Italy
-
Impax Laboratories, LLCCompletedIdiopathic Parkinson's DiseaseUnited States
-
Galapagos NVPRA Health SciencesCompleted